Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial

2017 ESMO Congress
Tweet this page

Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (Abstract 1043O).

Advertisement

Advertisement



Advertisement